French specialty vaccine company Valneva is planning to bring its chikungunya vaccine, the world’s first, to India.
Confirming that they were planning to make the vaccine available in India through their partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) and Instituto Butantan in Brazil, the spokesperson said the timeline would be determined after regulatory interactions with the DCGI. Responding to a query on whether CEPI was collaborating with vaccine manufacturers in India to bring this chikungunya vaccine to developing countries.
Biological E has indicated on its site that Valneva is a partner. In fact, Bharat Bio had started its Phase II/III trial in Costa Rica, in a partnership led by the International Vaccine Institute, the company had said in August 2021.
The mosquito borne chikungunya virus is primarily transmitted through the bite of an infected mosquito, and the infection is being reported from new geographical areas causing a global increase in prevalence, the USFDA had said, on approving the vaccine.
The International Vaccine Institute (IVI) is a nonprofit international organization established in 1997 as an initiative of the United Nations Development Programme (UNDP).
IVI is prohibited from manufacturing vaccines. Instead, we discover new vaccines, improve existing ones, and transfer vaccine technology to manufacturers for vaccine production.
An oral cholera vaccine and typhoid conjugate vaccine were developed in-house at IVI laboratories, and IVI is currently investing in preclinical development of two vaccine candidates for non-typhoidal Salmonella and Shigella
